Intracellular pathogens belonging to the genus Leishmania have developed effective strategies that enable them to survive within host immune cells. Immunostimulatory compounds that counteract such immunological escape mechanisms represent promising treatment options for diseases. Here, we demonstrate that a lipopeptidephosphoglycan (LPPG) isolated from the membrane of a protozoan parasite, Entamoeba histolytica (Eh), shows considerable immunostimulatory effects targeted against Leishmania (L.) major, a representative species responsible for cutaneous leishmaniasis (CL). Treatment led to a marked reduction in the number of intracellular Leishmania parasites in vitro, and ameliorated CL in a mouse model. We next designed and synthesized analogs of the phosphatidylinositol anchors harbored by EhLPPG; two of these analogs reproduced the anti-leishmanial activity of the native compound by inducing production of pro-inflammatory cytokines. The use of such compounds, either alone or as a supportive option, might improve the currently unsatisfactory treatment of CL and other diseases caused by pathogen-manipulated immune responses.
. Protective immune responses are mediated by cytokines such as IFNγ, inflammasome-activated IL-1β, TNFα, reactive oxygen species, and nitric oxide (NO) [12] [13] [14] . To date, no really effective therapeutic agents are available; therefore, new drugs are urgently required [15] [16] [17] [18] . Although NKT cells are thought to control Leishmania infection [19] [20] [21] , their activation by αGalCer or its synthetic derivate KRN7000 yielded controversial results, which seem to be strain-, host-, and organ-dependent. Treatment of L. donovani-or L. major-infected C57BL/6 mouse models of visceral leishmaniasis (VL) and CL, respectively, led to exacerbation of disease 22, 23 , whereas improvements were noted in BALB/c mouse models of CL 23 . Modification of the fatty acid chains (i.e., length and/or saturation) has a considerable influence on the immunological properties of this strong immune modulator, but no study has yet examined the therapeutic efficacy of these analogs against leishmaniasis 3, 24, 25 . Similar to E. histolytica, Leishmania parasites possess a glycophosphoconjugate lipophosphoglycan (LPG) moiety within the membrane, which acts as a virulence factor necessary for survival of the parasite in its vertebrate or eukaryotic host. The structure of the GPI anchor in the parasite is slightly different from that in E. histolytica in terms of the length and saturation of the fatty acids. The Leishmania LPG prevents the lysis of the parasite by the complement system and interferes with the pro-inflammatory immune response by engaging TLR2 and 4 on macrophages 26 . Here, we conducted both in vitro and in vivo (a BALB/c mouse model of CL) experiments to examine the efficacy of the moderate immune modulator EhLPPG as a treatment for infections caused by L. major. Because of the considerable disadvantages associated with the use of natural compounds for therapeutic purposes (reproducibility, cost, time, and the need for sophisticated purification steps), we here synthesized four analogs of the two EhLPPG GPI anchors, EhPIa and EhPIb, and investigated their capacity to stimulate cytokine production by immune cells of both murine and human origin, as well as their ability to ameliorate intracellular infection by L. major.
Results
Activity of native EhLPPG against L. major infection both in vitro and in vivo. In the first set of in vitro experiments, we asked whether treatment of L. major-infected murine bone marrow-derived macrophages (BMMs) with αGalCer or native EhLPPG would reduce the intracellular parasite load. We first examined the percentage of infected macrophages (Fig. 1a) and the Leishmania load in each individual macrophage in the presence/absence of spleen-derived lymphocytes (Fig. 1a,b) . We found that treatment with both αGalCer (1.0 µg/ml) and EhLPPG (8.0 µg/ml) led to a significant reduction in the percentage of infected macrophages (Control [Ctrl] , 43.9 ± 2.7%; αGalCer, 28.3 ± 1.5 [p < 0.0001]; EhLPPG, 22.4 ± 1.6 [p < 0.0001]). Addition of spleen-derived lymphocytes led to a further reduction in the percentage of infected macrophages (Ctrl, 39.8 ± 3.3%; αGalCer, 18.7 ± 1.8 [p < 0.0001]; EhLPPG, 20.6 ± 1.7 [p < 0.0001]) (Fig. 1a) . Treatment with αGalCer and EhLPPG also reduced the parasite load per macrophage (Ctrl, 5.3 ± 0.74; αGalCer, 3.
; however, addition of spleen cells had a stronger effect on the parasite/macrophage counts after αGalCer treatment than after EhLPPG treatment (Ctrl, 4.3 ± 0.5; αGalCer, 3.1 ± 0.4 [p = 0.05]; EhLPPG, 2.5 ± 0.3 [p < 0.0018]), supporting the notion that αGalCer is the more potent stimulator of peripheral immune cells (Fig. 1b) . Overall, EhLPPG exhibit a similar in vitro anti-leishmanial activity compared to αGalCer. To determine the therapeutic potential of EhLPPG, we subcutaneously (s.c.) injected the footpad of BALB/c mice with 2 × 10 5 metacyclic promastigotes. Beginning at around 4-5 weeks post-infection (p.i.), when the mice developed typical footpad swelling, the footpad was injected with either αGalCer (1.0 µg), EhLPPG (1.0 µg/4.0 µg/8.0 µg), or PBS (three times at weekly intervals). At around 5 weeks p.i., the degree of footpad swelling in PBS-treated control mice was similar to that in the treated groups (Fig. 1c) ; however, after the second treatment, we observed less footpad swelling in the treatment groups than in the control group, which became statistically significant after 6 weeks (Day 46 p.i.) (Ctrl, 4.7 ± 0.16 mm; αGalCer, (Fig. 1d) . To assess the effect of treatment on parasite spread, the draining lymph nodes were excised and analyzed by L. major actin-specific TaqMan PCR to detect parasites (Fig. 1e) . In contrast to αGalCer, treatment with EhLPPG led to a significant reduction in the parasite load (EhLPPG (1.0 µg), 155. (Fig. 2a) . Each comprise lysophosphatidylglycerol, which has a characteristic long-chain fatty acid of either 28 saturated carbons (C28:0) or 30 mono-unsaturated carbons (C30:1). EhPIb has an additional fatty acid at the 2-position of myo-inositol. Therefore, we synthesized an EhPIa analog with a C30:1 cis fatty acid structure (EhPIa C30:1 cis, 1) and three EhPIb analogs: EhPIb C30:1 cis (2), EhPIb C30:1 trans (3), and EhPIb C28:0 (4). The configuration of the glycerol moiety was not clearly determined by spectroscopy 7 ; therefore, we synthesized analogs 2, 3, and 4, which have sn-glycerol 1-phosphate moieties, as the model structure via 10a-10c using the chiral acyl glycerol 9a-9c.
In combination with newly developed phosphorylation methods used to synthesize EhPIa 1 27 , we developed a method for synthesizing inositol phospholipids harboring an unsaturated fatty acid. During synthesis, allyl and allyloxycarbonyl (alloc) groups were used to permanently protect the hydroxyl groups. The allyl and alloc groups could be removed under mild and neutral conditions incorporating transition metal catalysts. Here, we used a specially developed Ruthenium (Ru) catalyst (a cationic CpRu II complex) in combination with quinaldic acid, which was used as a catalytic deprotecting reagent 28 in the presence of an alcoholic solvent. Commonly used benzyl type protecting groups that can be removed by conventional hydrogenolysis were not applicable to the EhLPPG analogs due to their unsaturated fatty acid structure.
Synthesis of allyl/alloc-protected inositol building blocks was initiated from a mono-phosphorylated inositol intermediate 5 (Fig. 2b ) 27 . Transesterification of 5 to a benzyl ester under basic conditions yielded 6 (81% yield). p-Methoxybenzyl groups were then converted to alloc groups in a two-step protocol. After removal of the methoxymethyl group under an acidic condition, palmitic acid was used for the coupling reaction to yield 8. One of the benzyl esters in 8 was then cleaved by LiBr in acetone, and a mono-acylglycerol 9a, 9b, or 9c (harboring C30:1 cis, C30:1 trans, or C28:0 fatty acid structures, respectively) was introduced to yield 10a, 10b, or 10c, respectively, via the Mitsunobu reaction. After removal of the benzyl group with LiBr, we attempted global deprotection using the Ru complex and CH 2 Cl 2 /MeOH as a solvent system. However, not all alloc groups were removed. This was presumably caused by lithium salt of the phosphate from compound 8, which acted as a buffer and deprotonated the active form of the Ru complex. Addition of trifluoroacetic acid to the reaction system overcame this problem 29 , and the reaction proceeded smoothly under mild conditions to yield 2, 3, and 4 (with yields of 88%, 75%, and 82%, respectively) (see also Supporting information 1).
The synthetic EhLPPG analogs show only mild cytotoxicity. Due to their long, hydrophobic, single or double fatty acid chains, the synthetic analogs of the EhLPPG PI anchor may be cytotoxic to eukaryotic cells via potential insertion into the lipid bilayer (Fig. 3a) . Therefore, we tested the cytotoxicity of the molecules in two assays: a classical cytotoxicity assay, which determined the toxicity of new compounds against erythrocytes, and an assay based on murine or human lymphocytes. Human erythrocytes were incubated with different amounts of the synthetic analogs or water; the latter efficiently lyses erythrocytes within several minutes. Of all compounds tested, only EhPIb C30:1 cis showed (minimal) hemolysis at increasing concentrations (Fig. 3b) . Better assessment of cytotoxic properties can be achieved using eukaryotic lymphocytes. Here, we tested the time-and concentration-dependent cytotoxicity of the synthetic analogs against murine splenocytes and human peripheral blood mononuclear cells (PBMCs) by FACS analysis based on live/dead staining (Fig. 3c) .
In general, we observed a slight concentration-and time-dependent increase in the percentage of dead murine splenocytes in the presence of the synthetic analogs, which was more pronounced at higher concentrations; this was not the case for αGalCer and EhLPPG. However, EhPIb C30:1 cis appeared to be more cytotoxic than the other synthetic compounds or the native molecule itself. Only EhPIb C30:1 cis (at a concentration of 10 µg/ml for 24 h) was cytotoxic to PBMCs ( Fig. 3c ), suggesting that it has low potential in vivo cytotoxicity. We further investigated the toxicity of EhPIa C30:1 cis and EhPIb C30:1 cis using murine spleen-derived lymphocytes and human PBMCs (Fig. 3d ). As seen in Fig. 3c , murine lymphocytes appear more sensitive to the synthetic analogs than human lymphocytes. More specifically, we found that both analogs killed 50% of murine cells when used at a concentration of 50 µg/ml (EhPIa C30:1 cis: log IC 50 , 49.75; EhPIb C30:1 cis: log IC 50 , 49.39; DMSO: log IC 50 , 49.75). However, since the same concentration of DMSO alone exhibited a similar effect, we assumed that the toxicity might be attributed mostly to the solvent. By contrast, human peripheral lymphocytes were not lysed by DMSO or EhPIa C30:1 cis, even at the highest concentrations (100 µg/ml) tested. EhPIb C30:1 cis caused only minor cytotoxicity when used at a concentration of 100 µg/ml for 24 h. The data further suggest that the compounds would have low cytotoxicity in vivo.
Immunostimulatory characteristics of the synthetic EhLPPG analogs. The native molecule
EhLPPG was identified due to its immunostimulatory effect on NKT cells and macrophages 7, 8, 30 . To assess whether the synthetic analogs derived from this molecule still show favorable immunostimulatory properties, we investigated and characterized the cytokine profiles elicited by these compounds. The most convenient way to do this is to demonstrate intracellular cytokine production by NKT cells. Therefore, PBMCs from human blood donors were incubated with the synthetic compounds for several hours prior to FACS analysis. After gating on lymphocytes and including single cells and excluding dead cells, iNKT cells were identified as CD3 + hNKT-TCR + (Fig. 4a) . Figure 4b shows that a percentage of iNKT cells from one representative individual showed higher production of IFNγ and IL-4 after stimulation with αGalCer, EhLPPG, or the synthetic analogs than CD28-stimulated Ctrl NKT cells. We observed a significant increase in the percentage of IFNγ + iNKT cells following stimulation with αGalCer (30.9 ± 0.65; p = 0.029), EhLPPG (26.4 ± 0.3; p = 0.038), EhPIa C30:1 cis (34.75 ± 3.5; p = 0.032), and EhPIb C30:1 trans (29.9 ± 0.85; p = 0.03). IL-4 was induced by all molecules tested (Fig. 4c) . We also analyzed the broader cytokine spectrum in the supernatant of stimulated PBMC cultures using a cytometric bead assay (Fig. 4d) . Stimulation with αGalCer led to highly significant induction of pro-and anti-inflammatory cytokines, while stimulation with the native compound (EhLPPG) induced much lower cytokine levels, with greater induction of pro-inflammatory cytokines (i.e., IL-2, TNFα, IL-17, and IL-6) than anti-inflammatory cytokines (i.e., IL-10). Stimulation with EhPIa C30:1 cis induced levels of pro-inflammatory cytokine (IL-2, TNFα, IL-17A/F, and IL-6) production similar to those induced by the native molecule, but did not increase production of anti-inflammatory cytokines. EhPIb C30:1 cis also induced only pro-inflammatory cytokines (IL-2 and TNFα). EhPIb C30:1 trans induced TNFα and IL-6, whereas EhPIb C28:0 induced only TNFα (Fig. 4d) . Since we aimed to use the synthetic analogs as therapeutic agents in the mouse model of CL, we examined whether they induced IFNγ production by murine splenocytes or liver lymphocytes (the latter harbor the highest organ-specific concentration of iNKT cells in mice). A classical stimulation assay was therefore performed in which BMMs were generated and pulsed with the synthetic analogs for 48 h following addition of lymphocytes (splenocytes or liver lymphocytes). IFNγ levels in the culture supernatant were then measured in an ELISA. We observed significant induction of IFNγ following stimulation of splenocytes (Fig. 4e) and liver lymphocytes ( Fig. 4f) with αGalCer, EhLPPG, and EhPIb C30:1 cis. However, we observed only a slight increase in IFNγ production following stimulation of liver lymphocytes with EhPIb C30:1 cis (Fig. 4f) . Taken together, these data show that two out of the four synthetic analogs exhibited considerable immunostimulatory activity (EhPIa C30:1 cis on immune cells of human origin, and EhPIb C30:1 cis on immune cells of murine origin).
Treatment of murine and human macrophages with the EhPI analogs ameliorates L. major infection. Since treatment with native EhLPPG showed a parasite reducing effect, we next asked whether synthetic analogs EhPIa C30:1 cis, EhPIb C30:1 cis, EhPIb C30:1 trans, and EhPIb C28:0 had a similar impact on the intracellular L. major load. Therefore, we infected murine BMMs and human THP1 macrophages with L. major promastigotes (at stationary phase) and measured the intracellular Leishmania load using a Leishmania-specific TaqMan PCR 31 . We found that treatment of murine macrophages with αGalCer, EhLPPG, EhPIa C30:1 cis, or EhPIb C30:1 cis led to significant inhibition of parasite infection compared with that in infected but untreated from BMMs pulsed with αGalCer, EhLPPG, or the synthetic EhPI analogs and then incubated with murine (e) splenocytes and (f) liver lymphocytes for 48 h, as determined by ELISA. The following concentrations were used: αGalCer (1.0 µg/ml), EhLPPG (8.0 µg/ml), and synthetic EhPI analogs (1.0 µg/ml). Data are expressed as the mean ± SEM. *p < 0.05; **p < 0.01; and ***p < 0.001 (unpaired Student's t test (a-d) and Mann-Whitney U-test (e,f)).
SCIeNTIFIC REPORTS | 7: 9472 | DOI:10.1038/s41598-017-09894-8 (Fig. 5a ). However, there was no direct concentration-dependent correlation with the reduction in the parasite load. This may be due to the spontaneous formation of micelles by the amphiphilic fatty acid side chains of the synthetic analogs. We found it interesting that the L. major load increased following treatment of human macrophages with αGalCer, but fell following treatment with EhLPPG. Again, EhPIa C30:1 cis and EhPIb C30:1 cis (EhPIa C30:1 cis, 0.1 µg/ ml: 0.17 ± 0.095 [p = 0.000]; EhPIa C30:1 cis, 10.0 µg/ml: 0.44 ± 0.06 [p = 0.0002]; EhPIb C30:1 cis, 1.0 µg/ml: 0.65 ± 0.05 [p = 0.0004]; EhPIb C28:0, 0.1 µg/ml: 0.53 ± 0.0.094 [p = 0.003]) were the strongest inhibitors, while EhPIb C30:1 trans and αGalCer had no effect (Fig. 5b) .
To further characterize the treatment-specific, immunostimulatory effects of αGalCer, EhLPPG, the most promising analog (EhPIa C30:1 cis), and the least promising analog (EhPIb C28:0), we measured the levels of mRNA encoding infection-relevant protective cytokines (e.g., Il-12, Il-1β, Tnfα, Nos2 [iNOS]) and non-protective cytokines (Il-4, Il-10, Il-13, Tgf-β, and Arginase 1 [Arg1]) [12] [13] [14] in non-infected and infected murine macrophages (Fig. 5c) . Overall, EhLPPG induced the strongest infection-and treatment-specific increases in mRNA encoding protective cytokines (Il-1β, 2.7 ± 0.47 [p = 0.018]; NOS2, 4.9 ± 0.3 [p > 0.0001]); however, it had only a moderate effect on mRNA encoding non-protective cytokines (Il-10, 2.5 ± 1.2 [ns]). αGalCer increased the accumulation of mRNA encoding protective pro-inflammatory cytokines (Tnfα, 1.5 ± 0.29 [p = 0.018]) but induced a strong, although not statistically significant, increase in mRNA encoding non-protective cytokines Il-4 (1.8 ± 0.47, p = 0.1), Il-13 (145.9 ± 85.0, p = 0.1), and Arg1 (8.1 ± 5.3, p = 0.2). Treatment with EhPIa C30:1 cis showed inconsistent results, although there was a marked increase in expression of mRNA encoding Il-1β (3.8 ± 1.2, p = 0.06), one of the most relevant cytokines that protects against Leishmania parasites. We also observed an increase in expression of mRNA encoding anti-inflammatory cytokines Il-10 (2.7 ± 1.5, p = 0.2) and Il-13 (10.2 ± 6.8, p = 0.2). Treatment with EhPIb C28:0, an analog with only minimal immuno-and anti-leishmanial properties, led to an increase in mRNA encoding one non-protective cytokine (Il-4, 2.3 ± 0.4; p = 0.02), but no protective cytokines. To summarize, EhLPPG and EhPIa C30:1 cis tended to induce expression of mRNA encoding protective pro-inflammatory cytokines (Il-1β, Il-12, and Nos2).
Finally, we examined the therapeutic potential of the most promising analogs (EhPIa C30:1 cis and EhPIb C30:1 cis) in a BALB/c mouse model that is highly susceptible to CL. Mice were infected with L. major as described above and treated by local injection of each synthetic analog (5.0 µg) beginning at Week 3 p.i. Both synthetic analogs reduced footpad swelling when compared with the solvent control (DMSO) (Fig. 5d) . For EhPIb C30:1 cis, this difference was significant at Weeks 6 and 8 p.i. (p < 0.042* and p < 0.0046, respectively). However, the effect was temporary and the Leishmania lesions relapsed at Week 7 (although they remained smaller than those in Ctrl mice). We next determined the parasite load in a tissue lysate prepared from footpads at the time of sacrifice (Week 8 p.i.) but found no significant differences in the L. major actin DNA to mouse actin DNA ratio in lysates from treated mice or the DMSO ctrl group (DMSO ctrl: 1420 ± 768.9; EhPIa C30:1 cis: 1755 ± 831.7; EhPIb C30:1 cis: 3699 ± 1288; n = 4, mean ± SE) (Fig. 5e ). In addition, we found that treatment with EhPIa C30:1 cis and EhPIb C30:1 cis led to a significant reduction in the levels of anti-inflammatory cytokines IL-4 (EhPIa: p = 0.0002), IL-10 (EhPIa C30:1 cis: p = 0.0001; EhPIb C30:1 cis: p = 0.0001), and IL-13 (EhPIb C30:1 cis: p = 0.01), as well as C-C Chemokine Ligand 2, following treatment with EhPIbC30:1 cis (p = 0.02). This indicates that treatment results in a more favorable protective cytokine response since parasite survival depends on an anti-inflammatory Th2 type immune response (see Suppl. Figure 1) . Therefore, we conclude that, although the synthetic analogs reduce disease severity, this reduction is transient in a highly susceptible BALB/c mouse model of the disease.
Discussion
Intracellular pathogens such as Leishmania parasites that invade immune cells are very successful in manipulating the host immune response to circumvent their own clearance. Thus, without the support of the immune system, treatment and elimination of these agents is challenging. Most of the effective therapeutics used to treat VL target the parasite itself; however, they can have considerable side effects. These effects are often not tolerable in cases of the non-lethal and often self-limiting cutaneous form of the disease. There is no effective treatment for CL, although the options explored to date include surgery, curettage, laser, thermo-and cryotherapy, infiltration of the lesion with Pentostam, or the use of ointments containing paromocycin and methlybenzetonium 15, 17, 18, 32 . However, these therapies are either inconvenient or largely ineffective. Therefore, activating or re-activating the immune system using immunostimulatory molecules represents a promising strategy.
Here, we examined the ability of the immunostimulatory glycolipid EhLPPG, as well as newly synthesized analogs derived from its PI anchor, to stimulate a protective cytokine response in immune cells, and their efficacy against L. major, in in vitro and in vivo models.
We previously showed that EhLPPG induces production of IFNγ in a variety of immune cells such as murine spleen and liver lymphocytes, APCs, human and murine iNKT cells, and human PBMCs 8, 30 . In particular, specific stimulation of NKT cells, which shape the immune response after infection 33 , is a promising property of EhLPPG. Besides lymphocytic cells, APCs are activated by EhLPPG. We found that EhLPPG and EhPI activate APCs by binding to TLR2 or TLR6, leading to production of the pro-inflammatory cytokine IL-12 via engagement of MyD88. Simultaneously, EhLPPG is internalized and loaded on CD1d molecules. Both of these pathways are relevant for optimal NKT cell activation 8 . NKT cells also play an important role in immune responses during early stages of Leishmania infection; however, these responses appear to be dependent on the Leishmania species, mouse strain, and organ. For example, NKT cells contribute to clearance of L. donovani from the liver of BALB/c mice 20 but aggravate VL in C57BL/6 J mice 22 . During a L. major infection, the protection afforded by NKT cells s t test (a-k) ).
seems to be organ-specific in that the cells contribute to parasite elimination from the spleen and skin lesions, but not from the lymph nodes 21 . The experiments conducted herein show that the native molecule, EhLPPG, and the most potent NKT-agonist and immunomodulator, αGalCer, led to a significant reduction in the parasite burden in L. major-infected murine macrophages in vitro, an effect that increased slightly upon addition of spleen-derived lymphocytes (Fig. 1a) . Also, treatment of a mouse model of CL with EhLPPG had a positive effect on the disease outcome by reducing Leishmania-induced footpad swelling, increasing the time to euthanasia due to ulceration of the lesions and reducing parasite dissemination (Fig. 1c-e ). This agrees with previous findings showing that the αGalCer analog PBS57 delays lesion growth and reduces lesion size and parasite burden in BALB/c mice 23 . However, the same manuscript described exacerbation of disease pathology in C57BL/6 mice 23 . Most interestingly, another study shows that treatment of C57BL/6 mice with VL with αGalCer aggravates the disease due to increased production of non-protective IL-4 and reduces production of IFNγ + CD8 + T cells 22 . However, results obtained using native EhLPPG suggest that a synthetic version, produced under more reproducible conditions than the native compound, might represent a promising therapeutic agent. Since the complexity of the native EhLPPG molecule renders chemical synthesis impossible, we decided to focus on synthesis of the EhPI anchor. Certainly, synthesis of this anchor, which consists of two isoforms with one (EhPIa) or two (EhPIb) fatty acid chains and exhibits immunostimulatory properties, is more feasible 7 . Therefore, we designed and synthesized one analog that is very similar to EhPIa (EhPIa C30:1 cis) and three analogs that are similar to EhPIb (EhPIb C30:1 cis, EhPIb C30:1 trans, and EhPIb C28:0) ( Fig. 2; Fig. 3a) .
Due to their hydrophobic long fatty acid chains, the structure of the synthetic analogs may induce cytotoxicity via insertion into the lipid bilayer of eukaryotic cell membranes (as is the case for Miltefosine, a drug used to treat VL). Miltefosine also possesses a long single fatty acid chain that, among other things, is responsible for its hemolytic and cytotoxic activity 34, 35 . Therefore, we examined the hemolytic and cytotoxic activity of the synthetic analogs in vitro and found that only EhPIb C30:1 cis showed minor hemolytic activity and almost no cytotoxicity against human peripheral lymphocytes (Fig. 3) . We then examined the ability of the synthetic analogs to stimulate immune cells of either human or murine origin. We found that the analogs induced production of IFNγ and IL-4 by human NKT cells (Fig. 4a) ; therefore, we went on to characterize the cytokine profiles in the supernatants of stimulated human PBMCs. All synthetic analogs induced production of TNFα, while EhPIa induced production of pro-inflammatory cytokines (IL-2, IFNγ, IL-17, or IL-6). Prior analysis of modifications to the length of lipid chains in αGalCer suggested that a single chain analog like EhPIa would show similar or higher activity against human immune cells than a double chain analog like EhPIb, although αGalCer analogs with two lipid chains show higher affinity for murine immune cells 25 . As reported by others, we also found that αGalCer induced strong production of a broad variety of cytokines by PBMCs, indicating the critical potential of this immunostimulator to induce adverse immunological site effects and questioning its use for therapeutic purposes.
However, the synthetic analogs also activated macrophages. Indeed, some analogs reduced the L. major load in infected macrophages (Fig. 5a,b) . The most immunoactive analogs, EhPIa C30:1 cis and EhPIb C30:1 cis, yielded the most significant reduction in the L. major load, irrespective of whether the infected macrophages were murine or human. Strikingly, there was no dose-dependent effect on the Leishmania load; we can only speculate that this might be due to rapid and spontaneous formation of micelles, resulting in defective immune activation. However, this might be overcome by incorporating the synthetic analogs into suitable nanocarriers.
Macrophages are not only the main target cells for Leishmania parasites, but also the major effector cells required for parasite clearance. Generally, macrophages are activated by two distinct pathways: the classical and alternative pathways. Classical activation is mediated by cytokines such as IFNγ produced by T helper (Th)1 and natural killer cells, resulting in production of inducible nitric oxide synthase (iNOS or NOS2) by macrophages. iNOS and toxic NO kill intracellular bacteria and parasites, including Leishmania. Thus, classically activated macrophages are crucial for parasite elimination. Alternative macrophage activation is induced by IL-4 and IL-13 (Th2 cytokines), which upregulate arginase and polyamine biosynthesis. Because iNOS and arginase compete for the same substrate (L-arginine), upregulation of arginase can reduce iNOS activity and production of NO, resulting in parasite survival 12 . We assume that EhLPPG and the effective synthetic EhPI analogs activate and polarize macrophages via the classical pathway, a notion supported by the significantly higher expression of NOS2 mRNA in L. major-infected murine macrophages treated with EhLPPG. By contrast, expression of Arg1 mRNA did not differ from that in control cells. The mechanism seems to be a little different for EhLPPG and EhPIa C30:1 cis. L. major-infected murine macrophages treated with EhLPPG showed significantly higher expression of NOS2, IL-1β, and IL-12 mRNA, while infected macrophages treated with EhPIa C30:1 cis showed higher expression of only IL-1β and IL-12 mRNA. Thus, EhLPPG can directly stimulate NOS2 upregulation, possible via its sugar residues and greater ability to activate TLR signaling. Finally, the most immunoactive synthetic analogs, EhPIa C30:1 cis and EhPIb C30:1 cis, reduced the size of Leishmania lesions in a BALB/c mouse model of CL (Fig. 5) . Although only transient, the reductions induced by EhPIb C30:1 cis were significant. Further studies should examine in vivo effects using, for example, a less susceptible mouse model, synthetic analogs that are better protected from degradation, and combination therapy with anti-parasitic drugs.
Methods
Synthesis of EhLPPG analogs. The EhLPPG analogs EhPIa C30:1 cis (1) 27 , EhPIb C30:1 cis (2), EhPIb C30:1 trans (3), and EhPIb C28:0 (4) were chemically synthesized from compound 5 (Fig. 2a ) 27 . The detailed synthetic procedures and spectroscopic data are provided in the Supporting information.
Mice. C57BL/6 J and BALB/c mice were bred and kept under specific pathogen-free conditions in the animal facility at the Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
Determination of cytokine production by human NKT cells and human PBMCs and cytokine levels in tissue lysates. PBMCs were isolated from human blood donors by density gradient centrifugation and stimulated for 15 h with αGalCer (1.0 µg/ml), EhLPPG (8.0 µg/ml), EhPIa C30:1 cis (1.0 µg/ml), EhPIb C30:1 cis (1.0 µg/ml), EhPIb C30:1 trans (1.0 µg/ml), or EhPIb C28:0 (1.0 µg/ml) plus anti-CD28 (3.0 µg/ml) in X-VIVO ™ supplemented with 1% Pen/Strep (Lonza). Intracellular cytokines were measured following addition of Brefeldin A (10 µg/ml; 16 h) and staining for iNKT cell-specific surface markers (anti-CD3-PerCP and anti-TCRVα24-Jα18-APC; BioLegend).
Fixation and permeabilization steps (in Perm/Wash solution; 1:10; BD) were followed by staining with anti-IFNγ-PE/Cy7, anti-IL4-PE, and isotype control antibodies (BioLegend). Data were acquired using a BD LSRII flow cytometer and analyzed with FlowJo × 10.07 (Treestar). Tissue lysates were prepared from the footpads of infected and treated BALB/c mice. Briefly, footpads were sectioned and transferred directly to PBS buffer (200 µl) containing a protease inhibitor (Protease Inhibitor Tablets, SIGMAFAST). After adding the same volume of ceramic beads (diameter, 2 mm; Roth), the solution was minced using a tissue lyser (LT, QIAGEN), and centrifuged for 10 min at 13.000 × g at 4 °C. The cytokine profile in the tissue or culture supernatants (IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-17A, IL-17F, IL-21, IL-22, IFNγ, and TNFα) was assayed as described above (except in cases of Brefeldin A treatment) using the multi-LEGENDplex ™ analyte flow assay kit (Human Th Cytokine Panel, Cat.
No. 740001, BioLegend) according to the manufacturer's suggestions.
Measurement of cytokine production in stimulation assays based on spleen or liver lymphocytes. Bone marrow-derived dendritic cells were generated from BMMs by addition of GMCSF; the cells were then used as APCs 37 . Spleen cells were collected from perfused mouse spleen and subjected to erythrolysis. Perfused mouse livers were passed through a mesh filter and lymphocytes were purified by gradient centrifugation as described previously 7 . APCs were pulsed with αGalCer (1.0 µg/ml), EhLPPG (8.0 µg/ml), EhPIa C30:1 cis (1.0 µg/ml), EhPIb C30:1 cis (1.0 µg/ml), EhPIb C30:1 trans (1.0 µg/ml), or EhPIb 28:0 (1.0 µg/ml) for 3 h in the
